EVQLV

EVQLV is a developer of biocomputing technology aimed at transforming antibody design in biopharmaceuticals. The company’s platform conducts de novo design and antibody optimization, integrating into traditional discovery methods to uncover new biology. It combines antibody biological data with artificial intelligence to translate antibodies into clinical trials, providing customers with support during the discovery phase and accelerating the speed of antibody discovery.